Oncology Today with Dr Neil Love

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics:
Introduction (0:00)
Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17)
Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24)
Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28)
Management of Limited-Stage SCLC — Dr Ganti (1:31:54)

CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics:
Introduction (0:00)
HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08)
Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54)
Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:
Introduction (0:00)
Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)
Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)
Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)
Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)
Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)

CME information and select publications

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:
Introduction: Relative Impact of Targeted Treatment (00:00)
HER2 Alterations (8:04)
KRAS Mutations (24:25)
MET Overexpression (30:34)
ALK Fusions (32:34)
ROS1 Fusions (42:36)
RET Fusions (52:00)

CME information and select publications

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:
Introduction (0:00)
Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
Utility of Belantamab Mafodotin in R/R MM (49:29)
Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)

CME information and select publications